On the metabolic side, regulating the mTOR pathway is a clear avenue; transient mTOR inhibition might enforce a tolerant program (useful in cytokine storm or autoimmunity), whereas mTOR activation (for example via IGF1 or amino acid supplementation) might enhance training when needed for protection (though direct mTOR agonism is complex). The gene discussed is MTOR; the disease is Autoimmunity.